MCID: MCL027
MIFTS: 50

Macular Dystrophy, Dominant Cystoid

Categories: Eye diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 57 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 59 73
Cystoid Macular Dystrophy 57 59
Macular Edema, Cystoid 57 73
Dcmd 57 59
Cystoid Macular Dystrophy; Cymd 57
Familial Macular Edema 59
Macular Retinal Edema 73
Macular Edema 44
Cymd 57
Mddc 57

Characteristics:

Orphanet epidemiological data:

59
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

57
Inheritance:
autosomal dominant (7p21-p15)


HPO:

32
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

OMIM 57 153880
Disease Ontology 12 DOID:4447
MeSH 44 D008269
NCIt 50 C34794
SNOMED-CT 68 193387007
Orphanet 59 ORPHA75381
ICD10 via Orphanet 34 H35.5
MedGen 42 C0024440

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM : 57 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to retinitis pigmentosa and macular retinal edema, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy). The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are strabismus and hypermetropia

Related Diseases for Macular Dystrophy, Dominant Cystoid

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Symptoms via clinical synopsis from OMIM:

57
Eyes:
cystoid macular edema
whitish punctate vitreous deposits
moderate to high hyperopia
strabismus
diminished visual acuity
more
Radiology:
normal electroretinogram


Clinical features from OMIM:

153880

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 strabismus 32 HP:0000486
2 hypermetropia 32 HP:0000540
3 edema 32 HP:0000969
4 macular dystrophy 32 HP:0007754
5 pericentral retinitis pigmentosa 32 HP:0007947
6 cystoid macular edema 32 HP:0011505

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Dystrophy, Dominant Cystoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.02 BEST1 CRB1 MFRP PDE6A VEGFA

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
5
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 3154 5284549
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
9
Loteprednol Approved Phase 4,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
12
Linagliptin Approved Phase 4 668270-12-0 10096344
13
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
14
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
15
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2 378-44-9 9782
16
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
17
Ephedrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 299-42-3 9294
18
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 90-82-4 7028
19
Temazepam Approved, Investigational Phase 4,Phase 3,Not Applicable 846-50-4 5391
20
Azathioprine Approved Phase 4 446-86-6 2265
21
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
22
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
23
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
24
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
25
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
26
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
27
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
28
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 67-73-2 6215
29
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 74103-06-3, 66635-83-4 3826
30 Homatropine Approved Phase 4 87-00-3
31
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
32
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
33
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
34
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5282380 5311221
35
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 33624 5478
36
Travoprost Approved Phase 4 157283-68-6 5282226
37
Insulin Glargine Approved Phase 4 160337-95-1
38
Zinc Approved, Investigational Phase 4 7440-66-6 23994
39
Chlorambucil Approved Phase 4 305-03-3 2708
40
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
41
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
42
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
43
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
44
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
45
Empagliflozin Approved Phase 4 864070-44-0
46
Glimepiride Approved Phase 4 93479-97-1 3476
47
Alogliptin Approved Phase 4 850649-61-5 11450633
48
Metformin Approved Phase 4 657-24-9 14219 4091
49
Difluprednate Approved Phase 4 23674-86-4 443936
50
Fluprednisolone Approved Phase 4 53-34-9

Interventional clinical trials:

(show top 50) (show all 800)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Unknown status NCT02633852 Phase 4 Aflibercept
3 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
4 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
5 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
6 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
7 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
8 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
9 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
10 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
12 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
13 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
14 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
15 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
16 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
17 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
18 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
19 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
20 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
21 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
22 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
23 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
24 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
25 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
26 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
27 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
28 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
29 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
30 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
31 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
32 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
33 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
34 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
35 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept
36 Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
37 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
38 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
39 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
40 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
41 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
42 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
43 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
44 CME With Different Fluidic Parameters Completed NCT01385852 Phase 4
45 Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
46 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
47 A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema Completed NCT01315275 Phase 4 Ranibizumab
48 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
49 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
50 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4 Ranibizumab

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

41
Eye, Endothelial, Retina, Testes, Bone, Monocytes, Thyroid

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 583)
# Title Authors Year
1
Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial. ( 29120255 )
2018
2
Is it melanoma-associated retinopathy or drug toxicity? Bilateral cystoid macular edema posing a diagnostic and therapeutic dilemma. ( 29780921 )
2018
3
Treatment of cystoid macular edema in homozygous twins with glutathione synthetase deficiency and retinal dystrophy. ( 29395598 )
2018
4
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. ( 29855706 )
2018
5
CHANGES IN CHOROIDAL THICKNESS IN CLINICALLY SIGNIFICANT PSEUDOPHAKIC CYSTOID MACULAR EDEMA. ( 28654631 )
2017
6
CYSTOID MACULAR EDEMA AND CYSTOID MACULAR DEGENERATION AS A RESULT OF MULTIPLE PATHOGENIC FACTORS IN THE SETTING OF CENTRAL SEROUS CHORIORETINOPATHY. ( 27902539 )
2017
7
Cystoid Macular Edema with Idiopathic Acute Central Retinal Artery Occlusion in a Healthy Child. ( 28791072 )
2017
8
Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. ( 28608031 )
2017
9
Cystoid Macular Edema in Retinitis Pigmentosa with Intermediate Uveitis Responded Well to Oral and Posterior Subtenon Steroid. ( 28353369 )
2017
10
CYSTOID MACULAR EDEMA SECONDARY TO RITUXIMAB. ( 28267110 )
2017
11
Comparison of Subtenon Triamcinolone Acetonide Injection with Topical Nepafenac for the Treatment of Pseudophakic Cystoid Macular Edema. ( 27015572 )
2017
12
Vitreous hyper-reflective dots in pseudophakic cystoid macular edema assessed with optical coherence tomography. ( 29244855 )
2017
13
Treatment of cystoid macular edema after cataract surgery. ( 28366377 )
2017
14
ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. ( 28834951 )
2017
15
Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. ( 26778329 )
2016
16
Relationship between metamorphopsia and foveal microstructure in patients with branch retinal vein occlusion and cystoid macular edema. ( 27169934 )
2016
17
Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. ( 27858937 )
2016
18
Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery. ( 26929630 )
2016
19
[Tolerability and short-term efficacy of the OzurdexAr dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital]. ( 26616298 )
2016
20
Cystoid macular edema associated with iridocorneal endothelial syndrome: a case report. ( 27585567 )
2016
21
Impact of allergy and atopy on the risk of pseudophakic cystoid macular edema. ( 27553052 )
2016
22
Structure-function Relationships in Uveitic Cystoid Macular Edema: Using En Face Optical Coherence Tomography to Predict Vision. ( 26471011 )
2016
23
Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty as a Staged and Solitary Procedure. ( 27158809 )
2016
24
Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide. ( 27521675 )
2016
25
Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. ( 27224076 )
2016
26
Transient corneal edema is a predictive factor for pseudophakic cystoid macular edema after uncomplicated cataract surgery. ( 25646056 )
2015
27
Management of pseudophakic cystoid macular edema. ( 25438734 )
2015
28
Incidence and Characteristics of Cystoid Macular Edema after Cataract Surgery. ( 26560833 )
2015
29
The Characteristics and Short-term Refractive Error Outcomes of Cystoid Macular Edema in Premature Neonates as Detected by Spectral-Domain Optical Coherence Tomography. ( 26431295 )
2015
30
Epiretinal membrane and cystoid macular edema after retinal detachment repair with small-gauge pars plana vitrectomy. ( 25907288 )
2015
31
Cystoid Macular Edema and Macular Pigmentation Associated with Nab-Paclitaxel Theraphy. ( 25764317 )
2015
32
Pathophysiology of transient corneal edema and pseudophakic cystoid macular edema. ( 26028950 )
2015
33
Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant. ( 26222112 )
2015
34
Differentiation of Diabetic Macular Edema From Pseudophakic Cystoid Macular Edema by Spectral-Domain Optical Coherence Tomography. ( 26567783 )
2015
35
The discrepancy between central foveal thickness and best corrected visual acuity in cystoid macular edema secondary to central retinal vein occlusion after intravitreal lucentisAr injection. ( 25818575 )
2015
36
Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. ( 25559510 )
2015
37
Longitudinal analysis of the structural pattern of pseudophakic cystoid macular edema using multimodal imaging. ( 25863671 )
2015
38
Bilateral cystoid macular edema following docetaxel chemotherapy in a patient with retinitis pigmentosa: a case report. ( 25885440 )
2015
39
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. ( 25670491 )
2015
40
Posterior microphthalmos and papillomacular fold-associated cystic changes misdiagnosed as cystoid macular edema following cataract extraction. ( 25609908 )
2015
41
CRB1-Related Maculopathy With Cystoid Macular Edema. ( 26312378 )
2015
42
Comparison of topical dorzolamide and ketorolac treatment for cystoid macular edema in retinitis pigmentosa and Usher's syndrome. ( 25428176 )
2015
43
Poorer neurodevelopmental outcomes associated with cystoid macular edema identified in preterm infants in the intensive care nursery. ( 25439600 )
2015
44
Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. ( 25892932 )
2015
45
Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane). ( 26366312 )
2015
46
EFFICACY AND SAFETY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR PERSISTENT UVEITIC CYSTOID MACULAR EDEMA. ( 25741813 )
2015
47
Gyrate atrophy of the choroid and retina with cystoid macular edema and unilateral optic disc drusen. ( 25643373 )
2015
48
Effect of interferon I+2a in cystoid macular edema due to intraocular infection. ( 25790810 )
2015
49
THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion. ( 25748280 )
2015
50
Incidence of cystoid macular edema: Femtosecond laser-assisted cataract surgery versus manual cataract surgery. ( 25724279 )
2015

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 6, 64431408: 64431408
2 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 6, 63721512: 63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

GO Terms for Macular Dystrophy, Dominant Cystoid

Cellular components related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.13 CRB1 KCNMA1 MFRP
2 photoreceptor inner segment GO:0001917 8.62 CRB1 MAK

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.13 BEST1 MFRP PDE6A
2 eye photoreceptor cell development GO:0042462 8.8 CRB1 MFRP VEGFA

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....